In addition, metformin and many other compounds were used to lower aortic TXNIP levels in vivo or endothelial levels in vitro to block NLRP3 inflammasome activation and protect from endothelial dysfunction and cardiovascular risk factors (72, 73, 74, 75, 76). Here, TXNIP is linked to endothelial dysfunction.